Purchase this article with an account.
E. S. Lopez, J. Croxatto, A. Kvanta, J. Gallo; Suramab, a Pharmaceutical Compound of Bevacizumab and Suramin, Strongly Inhibits Vessels Growth in a Rabbit Model of Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1491. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In previous studies we showed that intravenous Suramin (20 mg/kg) and Bevacizumab (5 mg/kg), separately, diminished corneal neovascularization. The present study aims to evaluate a possible synergistic effect of the two drugs.
Corneal NV was induced in two groups of nine White New Zealand rabbits, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group one was treated after injury with intravenous Suramab at a doses equivalent to 3mg./kg of bevacizumab and 10mg./kg of suramin. The control group received no treatment. Digital photographs were taken at days 9, 15, 21 and 35. NV index (NVI) was calculated using the jimage program. Neovessels formation was quantified given a score from 0 to 4 to each quadrant according to the centripetal growth of the longest vessel. Scores of the four quadrants were summed to obtain the NVI.
Nine days after injury, the NVI was much higher in the control group (mean 4.7) than in the treated group (mean 1.5). Suramab significantly reduced neovessels formation (mean 6.1) compared with control animals (mean 13) at 35 days(p<0,01).
The systemic application of Suramab reduced corneal neovascularization. Duration of the effect was longer than that previously obtained with higher monodoses of Bevacizumab and Suramin. Results suggest the presence of pharmacological synergia.
This PDF is available to Subscribers Only